CD19 and acute lymphoblastic leukemia: The anti-B4-blocked ricin MoAb was used in a frontline CALGB study in patients with CD19+ ALL instead of high-dose cytarabine consolidation, reserved to CD19-negative ALL patients.53 Forty-six patients were treated.